This all or nothing story is not unique to gantenerumab.
FORBES: The Difficulties In Predicting Blockbuster Drugs
2.
Despite the fact that other inhibitors of beta-amyloid have failed in clinical trials, Roche is moving ahead with gantenerumab to see if early intervention in patients at risk for AD can stave off disease.
FORBES: The Difficulties In Predicting Blockbuster Drugs